IntegraGen’s Core Strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases. Development and commercialization activities are currently focused on Autism, Diabetes, Obesity and Bi-Polar disorders. In-licencing and out-licensing are key strategic levers.
IntegraGen's Enabling Strategy leverages internal competencies , provides a foundation for future offerings and generating an in-flow of cash. The Genetic Services Business provides Genotyping Services and BAC-Array Chips to the research community. IntegraGen's Center of Excellence for Diabetes, based in Bonn Germany, is ISO accredited and provides four highly specialized molecular diagnostic tests to healthcare professionals.
Our Business Model uses partnering to fund IP growth
Competitive Advantage
Our Competitive Advantage derives from the alignment of the company's valuable resources:
- Our People are dedicated and world-class Scientists, Bio-Statisticians and Technicians.
- Our Technology, GenomeHIP™, is breakthrough. It is fast, cost-effective, and highly accurate in identifying causal genes.
- Our Partners provide complementary expertise and privileged access to unique patient collections.
